BioSpace News Archive

Bio NC

HEMOSONICS APPOINTS DR. BRUCE SPIESS AS MEDICAL DIRECTOR AND EXHIBITS DIAGNOSTIC SOLUTIONS AT ANESTHESIOLOGY®, THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS (ASA) ANNUAL MEETING

Newly appointed Medical Director, Bruce Spiess, MD, FAHA to moderate the educational session “Listening to the Blood: An Update on the Quantra® System, the Latest Technology in the Management of Critical Bleeding”

October 21, 2022
·
4 min read
Biotech Bay

Asher Bio to Present First Preclinical Data for AB359, its CD8-targeted IL-2 Immunotherapy for Hepatitis B at AASLD 2022

Asher Biotherapeutics, Inc. today announced that it will present the first preclinical data for AB359.

October 21, 2022
·
2 min read
Pharm Country

Almirall PROSES study demonstrates appropriate acne treatment decreases the burden of impact on acne sufferers’ social and emotional wellbeing

Almirall, LLC, a global biopharmaceutical company focused on skin health, is excited to announce the release of its privately funded PROSES study at this year’s Fall Clinical Dermatology Conference® in Las Vegas, Nevada, October 20-23, 2022.

October 21, 2022
·
10 min read
Business

BIOQUAL Presents Unaudited Financial Results for First Quarter of Fiscal Year 2023

For more detail related to the fiscal year 2023 unaudited first quarter results, please visit BIOQUAL website.

October 21, 2022
·
1 min read
Business

Bruker Announces Date and Time of Third Quarter 2022 Earnings Release and Webcast

Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2022 financial results before market opening on Thursday, November 3, 2022.

October 21, 2022
·
2 min read
Pharm Country

Thubrikar Aortic Valve completes initial CE Mark-enabling TAVI-1 Study

Thubrikar Aortic Valve, Inc., announced today that it has completed the initial CE Mark-enabling study using the Optimum Transcatheter Aortic Valve (Optimum TAV™) in patients with severe aortic stenosis.

October 21, 2022
·
3 min read
BioCapital

Aditxt’s (Nasdaq: ADTX) Adimune™ Program Has Initiated the Manufacturing Process of Immunotherapeutic Drug Candidate, ADI™-100 in Preparation for Planned Psoriasis First-in-Human Trials

Aditxt, Inc. today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during the second half of 2023.

October 21, 2022
·
4 min read
Drug Development

Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy

Sermonix Pharmaceuticals Inc. today shared additional findings from its Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE 1) Phase 2 study during the 4th Annual Congress of the International Society of Liquid Biopsy (ISLB) in Miami.

October 21, 2022
·
4 min read
Business

GlycoPath Inc. Applies Proprietary Technology to Lyme Disease to Distinguish Among Disease States and Track Treatment Response

GlycoPath’s proprietary GlycoTyper™ immunoaffinity technology was used to distinguish between Lyme disease infection states and track treatment response through a collaboration with Drexel University College of Medicine, Philadelphia, PA.

October 21, 2022
·
2 min read
Nabsys reveals new details about their next generation whole-genome mapping technology and partnership with Hitachi High-Tech

In whitepapers posted to the company’s website this week, Nabsys has provided new details into its next generation HD-Mapping™ platform.

October 21, 2022
·
3 min read